针对SLFN11受调节的途径恢复了AML中的化疗敏感性
Sara H Small1,2,3,4, Ricardo E Perez1, Elspeth M Beauchamp1,2,5
1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
Blood neoplasia
|June 24, 2025
概括
施莱芬11 (SLFN11) 的低表达预测了急性髓性白血病 (AML) 的不良结果. 恢复SLFN11功能或抑制ATR通路可能会克服AML患者的化学抵抗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 化学抵抗是治疗急性髓性白血病 (AML) 的一个主要障碍.
- 了解抗药性机制对于开发有效的AML疗法至关重要.
研究的目的:
- 调查Schlafen 11 (SLFN11) 在AML化学抵抗中的作用.
- 确定SLFN11作为AML的潜在治疗点.
主要方法:
- 与患者存活率和预后相关联的SLFN11表达.
- 评估SLFN11水平对AML细胞亡和化疗敏感性的影响.
- 研究ATR/Chk1通路在SLFN11介导化学抵抗中的作用.
- 评估SLFN11淘汰AML细胞对不同治疗剂的敏感性.
主要成果:
- 低SLFN11表达与AML患者的生存率和预后不佳有关.
- SLFN11调节化疗敏感性;其抑制通过ATR/Chk1激活导致细胞氨基酸抗性.
- 抑制ATR通路恢复了低SLFN11.11的AML细胞中的细胞氨酸敏感性.
- SLFN11淘汰AML细胞对低甲基化剂和venetoclax仍然敏感.
结论:
- SLFN11是AML中化疗敏感性的关键调节器和预测器.
- 针对SLFN11抑制的途径可能提供新的组合疗法,以改善AML治疗结果.
更多相关视频
10:09Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
8.4K
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.3K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
